QDEL QuidelOrtho Corp
Debt Financing ·
Bank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026.
We have not published a story on QuidelOrtho yet. When there is news, it will appear here.
| Line | FY ended Dec 28, 2025 | FY ended Dec 29, 2024 |
|---|---|---|
| Revenue | $2.73 billion | $2.78 billion |
| Research and development | $186.2 million | $218.7 million |
| Net income (loss) | -$1.13 billion | -$2.05 billion |
| Cash from operations | $105.2 million | $83.0 million |
| Cash and equivalents | $169.8 million | $98.3 million |
| Short-term investments | $0 |
QuidelOrtho Corp trades under the ticker QDEL on NASDAQ.
QuidelOrtho Corp is listed on NASDAQ.
Our directory records QuidelOrtho Corp under United States.
aibio.space lists QuidelOrtho Corp among 2,820 public biotech companies and publishes its news here as stories appear.
$2.73 billion for the fiscal year ended Dec 28, 2025, as reported to the SEC.
QuidelOrtho Corp reported a net loss of $1.13 billion for the fiscal year ended Dec 28, 2025, and generated $105.2 million of cash from operations, per its annual report to the SEC.
$186.2 million in the fiscal year ended Dec 28, 2025, per its annual report.
$123.4 million in cash at Jun 28, 2026, per its 10-Q.
Our latest story on QuidelOrtho, dated Sep 23, 2026: "QuidelOrtho amends credit agreement and resets covenant levels to 2029". Bank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026. Source.
Our latest debt story, dated Sep 23, 2026: "QuidelOrtho amends credit agreement and resets covenant levels to 2029". Bank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026. Source.
Press Follow on this page to add QuidelOrtho to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming QuidelOrtho so far, in Debt Financing.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio